“We are very pleased with the progress of both our co-lead programs as we advance into what could be a transformative year for our company,” said Lawrence Klein, Chief Executive Officer of Oruka. “Given strong site engagement and enthusiasm, EVERLAST-A completed enrollment in December 2025, enabling us to bring our initial data release into the second quarter of 2026. Meanwhile, we are excited to be starting our Phase 2 efforts with ORKA-002, which we believe could be a very impactful program in psoriatic disease and HS.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka’s ORKA-001 Extension Study Builds Long-Term Case in Psoriasis Market
- Is ORKA a Buy, Before Earnings?
- Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy
- Oruka Therapeutics price target raised to $45 from $42 at Wedbush
- Oruka Therapeutics price target raised to $71 from $46 at Clear Street